Healthcare provider profile · identity verified

Michael C Kumin, MD

Family Practice · SOUTH BERWICK, ME · NPI 1184795205

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	448	137
Lisinopril	Lisinopril	222	66
Amlodipine Besylate	Amlodipine Besylate	185	60
Levothyroxine Sodium	Levothyroxine Sodium	153	37
Omeprazole	Omeprazole	135	45
Rosuvastatin Calcium	Rosuvastatin Calcium	118	38
Metformin Hcl Er	Metformin Hcl	113	33
Hydrochlorothiazide	Hydrochlorothiazide	112	37
Losartan Potassium	Losartan Potassium	109	33
Metoprolol Succinate	Metoprolol Succinate	99	32
Albuterol Sulfate Hfa	Albuterol Sulfate	94	40
Simvastatin	Simvastatin	85	26
Pantoprazole Sodium	Pantoprazole Sodium	71	20
Atenolol	Atenolol	69	20
Tamsulosin Hcl	Tamsulosin Hcl	69	27
Duloxetine Hcl	Duloxetine Hcl	67	17
Ozempic	Semaglutide	63	14
Furosemide	Furosemide	54	17
Gabapentin	Gabapentin	54	20
Alprazolam	Alprazolam	53	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	53	14
Sertraline Hcl	Sertraline Hcl	53	18
Metformin Hcl	Metformin Hcl	49	16
Glipizide Er	Glipizide	44	11
Jardiance	Empagliflozin	44	12
Trazodone Hcl	Trazodone Hcl	44	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	42	17
Clonazepam	Clonazepam	37	suppressed
Citalopram Hbr	Citalopram Hydrobromide	31	suppressed
Lorazepam	Lorazepam	31	15
Allopurinol	Allopurinol	30	suppressed
Mirtazapine	Mirtazapine	30	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	29	suppressed
Trulicity	Dulaglutide	29	suppressed
Eliquis	Apixaban	28	suppressed
Ondansetron Odt	Ondansetron	26	13
Famotidine	Famotidine	25	suppressed
Potassium Chloride	Potassium Chloride	25	suppressed
Azelastine Hcl	Azelastine Hcl	24	suppressed
Lovastatin	Lovastatin	24	suppressed
Carvedilol	Carvedilol	23	suppressed
Rybelsus	Semaglutide	23	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	23	suppressed
Propranolol Hcl	Propranolol Hcl	22	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	21	suppressed
Spironolactone	Spironolactone	19	suppressed
Valsartan	Valsartan	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	18	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	suppressed
Aripiprazole	Aripiprazole	17	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Finasteride	Finasteride	17	suppressed
Lansoprazole	Lansoprazole	17	suppressed
Sildenafil Citrate	Sildenafil Citrate	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Colchicine	Colchicine	16	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Diazepam	Diazepam	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Prednisone	Prednisone	13	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Effexor Xr	Venlafaxine Hcl	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Glipizide	Glipizide	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Vraylar	Cariprazine Hcl	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Naproxen	Naproxen	11	suppressed
Olanzapine	Olanzapine	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error